Biologics-na�ve Juvenile Idiopathic Arthritis (JIA) patients may have an increased risk of cancer compared with the general Swedish population, according to research presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

( European League Against Rheumatism ) Biologics-naive juvenile idiopathic arthritis patients may have an increased risk of cancer compared with the general Swedish population, according to research presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. Results of an additional study, which researched a small cohort of patients showed an ...

TEL AVIV, Israel----VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of preclinical data from the companys lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology.

Teva Pharmaceutical Industries Ltd. is testing a copy of Roche Holding AGs second-biggest-selling drug Rituxan in what may be the first U.S. generic version of a monoclonal antibody, a protein-based medicine used to treat diseases ranging from arthritis to cancer.

May 25 (Bloomberg) -- Teva Pharmaceutical Industries Ltd. is testing a copy of Roche Holding AG s second-biggest-selling drug Rituxan in what may be the first generic version of a monoclonal antibody, a protein-based medicine used to treat diseases ranging from arthritis to cancer.